Compare BBAI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBAI | PCRX |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | BBAI | PCRX |
|---|---|---|
| Price | $6.41 | $26.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 97.9M | 687.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $144,199,000.00 | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | $22.91 | $9.53 |
| P/E Ratio | ★ N/A | $55.72 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $2.36 | $18.17 |
| 52 Week High | $10.36 | $27.64 |
| Indicator | BBAI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 72.55 |
| Support Level | $6.35 | $23.63 |
| Resistance Level | $7.00 | $24.81 |
| Average True Range (ATR) | 0.53 | 0.93 |
| MACD | 0.07 | 0.25 |
| Stochastic Oscillator | 55.01 | 100.00 |
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.